Patent · US Expired

Human prostatic specific reductase

US5786204A · kind A · utility

29Cited by
2References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 5, 1995
Grant dateJul 28, 1998
Priority date
Expiry dateJun 5, 2015

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2500/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A human prostatic specific reductase polypeptide and polynucleotides encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides as a diagnostic marker for prostate cancer and as an agent to determine if the prostate cancer has metastasized. Also disclosed are antibodies specific to the prostatic specific reductase polypeptide which may be used to target prostate cancer cells and be used as part of a prostate cancer vaccine. Methods of screening for agonists and antagonists for the polypeptide and therapeutic uses of the antagonists are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.